Cellecta's DECIPHER Project RNAi Screening Tools at Roswell Park Cancer Institute

We have started this blog as a simple, unobtrusive conduit that enables us to talk directly to our customers, collaborators, and other interested researchers about new and interesting developments related to Cellecta’s technology and business. As the first post, we thought we would tell you about our recent agreement with the Roswell Park Cancer Institute (RPCI) that provides support to laboratories in their institution doing genome-wide RNAi screenings using our expanding portfolio of open-access DECIPHER™ pooled lentiviral shRNA expression libraries.

Although the plasmid versions of the DECIPHER shRNA library "modules" are available free-of-charge to any academic laboratory though the DECIPHER Project (www.decipherproject.net), the DECIPHER Technology Access and Maintenance (TAM) Program, which the RPCI just joined, lets them make this screening technology accessible through a well-supported centralized core facility. The DECIPHER TAM Program enables us to provide this institution with new modules of the packaged, ready-to-use shRNA expression libraries as they are developed, proactive support for all the labs using these resources, updates on new technological developments and protocols, and access to the latest software to analyze screening results.

Currently, as part of the open-access DECIPHER Project, there are 4 pooled shRNA library modules freely available—two modules targeting 10,000 human genes and two targeting 10,000 mouse genes. Each individual library module targets approximately 5,000 well-annotated genes with 27,500 shRNAs (5-6 shRNA target each transcript). Human and mouse 1 modules target that same set of genes related to signal transduction and cancer. The second modules target a broader range of genes that appear to be involved in disease processes and pathology but were not targeted in the first module. In a few weeks, we will release a human module 3 targeting 5,000 genes. Ultimately, there will be 5 modules targeting all human genes. As with all of our libraries, we utilize bar-coded inserts and have checked the quality of the DECIPHER modules using HT sequencing to ensure all shRNA sequences are present at sufficient levels to ensure comprehensive screening of the targeted gene set.

The ability to identify genes with specific functional activities makes screening with pooled shRNA expression libraries a very powerful technique to investigate the genetic controls regulating a wide range of biological responses. However, effective screening can be technically challenging. While the DECIPHER Project is helping to fulfill our goal to make basic tools for this type of analysis readily available to all labs, the DECIPHER TAM Program allows us to provide the resources and support that will empower labs to utilize these RNAi screening tools to their maximum potential. We are really looking forward to working with RPCI on this program.

More information about the DECIPHER Project can be found on www.decipherproject.net.

Leave a comment

Comments will be approved before showing up.

Also in Cellecta Blog & News

Inducible Cas9 Expression in a Single Lentiviral Vector

Introducing Inducible Cas9 Expression in a Single Lentiviral Vector to make cells capable of high Cas9 expression for a limited time during which CRISPR-mediated targeted rearrangements can occur, and then shut off Cas9 expression for downstream assays with the modified cells.
Read More
Insertion of 10X Genomics' Capture Sequences Does Not Affect HEAT-Tracr sgRNA Efficacy

Perturb-Seq or CROP-Seq screens make use of single-cell RNA-Sequencing in conjunction with a pooled CRISPR library to identify transcriptional changes and, by implication, activation or deactivation of cellular pathways related to phenotypic changes produced by specific sgRNA-mediated gene knockouts.
Read More
Core Population of Cancer Stem Cells Mediates Therapeutic Resistance in Tumors

Researchers at MD Anderson Cancer Center recently used a Cellecta CloneTracker Barcode Library to label patient-derived xenograft (PDX) cells and establish a stable population of aggressive tumorigenic cells with a specific set of barcodes. With this population of barcoded tumorigenic clones, the investigators...
Read More